Secondary cytoreduction in ovarian cancer: who really benefits?

Maria Teresa Giudice, Marco D’Indinosante, Serena Cappuccio, Valerio Gallotta, Anna Fagotti, Giovanni Scambia, Marco Petrillo

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Purpose: To identify women affected by recurrent ovarian cancer who benefit from secondary cytoreductive surgery (SCS), analyse their clinical and biological features and investigate the role of minimally invasive surgery (MIS) and hyperthermic intraperitoneal-based chemotherapy (HIPEC) in this subset of patients. Methods: This narrative review examines the data available from the updated literature. An electronic literature search was conducted in PubMed Medline databases for articles published from 1990 to 2018. Results: Retrospective studies and preliminary data from the AGO-Desktop III trial show that cytoreductive surgery is associated with improved post-relapse survival in patients with platinum-sensitive relapse, compared to chemotherapy alone. This benefit is more evident in patients treated with complete or optimal primary debulking surgery at referral centres, who did not receive bevacizumab in first-line chemotherapy, and who present a localized pattern of disease. MIS has been proven to be a favourable approach to achieve a complete secondary debulking, reducing peri- and postoperative comorbidities. The application of HIPEC to SCS is associated with an improvement in oncological outcomes by preliminary results. Conclusions: While waiting for the final results of the ongoing randomized controlled trials, SCS seems feasible and safe in selected patients with recurrent ovarian cancer. Recently, more attention has been focused on the biological features of ovarian tumours, such as BRCA status. Further studies and molecular research should be conducted to identify individualized and targeted therapies in the treatment of ovarian cancer recurrences.

Original languageEnglish
Pages (from-to)873-879
Number of pages7
JournalArchives of Gynecology and Obstetrics
Volume298
Issue number5
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Ovarian Neoplasms
Drug Therapy
Minimally Invasive Surgical Procedures
Recurrence
Platinum
PubMed
Comorbidity
Referral and Consultation
Randomized Controlled Trials
Retrospective Studies
Databases
Survival
Therapeutics
Research
Neoplasms

Keywords

  • Biological features
  • Minimally invasive surgery
  • Personalized treatment
  • Recurrent ovarian cancer
  • Secondary cytoreductive surgery

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Secondary cytoreduction in ovarian cancer : who really benefits? / Giudice, Maria Teresa; D’Indinosante, Marco; Cappuccio, Serena; Gallotta, Valerio; Fagotti, Anna; Scambia, Giovanni; Petrillo, Marco.

In: Archives of Gynecology and Obstetrics, Vol. 298, No. 5, 01.11.2018, p. 873-879.

Research output: Contribution to journalReview article

Giudice, Maria Teresa ; D’Indinosante, Marco ; Cappuccio, Serena ; Gallotta, Valerio ; Fagotti, Anna ; Scambia, Giovanni ; Petrillo, Marco. / Secondary cytoreduction in ovarian cancer : who really benefits?. In: Archives of Gynecology and Obstetrics. 2018 ; Vol. 298, No. 5. pp. 873-879.
@article{016ffafadbb94118ad70a24fbb257b72,
title = "Secondary cytoreduction in ovarian cancer: who really benefits?",
abstract = "Purpose: To identify women affected by recurrent ovarian cancer who benefit from secondary cytoreductive surgery (SCS), analyse their clinical and biological features and investigate the role of minimally invasive surgery (MIS) and hyperthermic intraperitoneal-based chemotherapy (HIPEC) in this subset of patients. Methods: This narrative review examines the data available from the updated literature. An electronic literature search was conducted in PubMed Medline databases for articles published from 1990 to 2018. Results: Retrospective studies and preliminary data from the AGO-Desktop III trial show that cytoreductive surgery is associated with improved post-relapse survival in patients with platinum-sensitive relapse, compared to chemotherapy alone. This benefit is more evident in patients treated with complete or optimal primary debulking surgery at referral centres, who did not receive bevacizumab in first-line chemotherapy, and who present a localized pattern of disease. MIS has been proven to be a favourable approach to achieve a complete secondary debulking, reducing peri- and postoperative comorbidities. The application of HIPEC to SCS is associated with an improvement in oncological outcomes by preliminary results. Conclusions: While waiting for the final results of the ongoing randomized controlled trials, SCS seems feasible and safe in selected patients with recurrent ovarian cancer. Recently, more attention has been focused on the biological features of ovarian tumours, such as BRCA status. Further studies and molecular research should be conducted to identify individualized and targeted therapies in the treatment of ovarian cancer recurrences.",
keywords = "Biological features, Minimally invasive surgery, Personalized treatment, Recurrent ovarian cancer, Secondary cytoreductive surgery",
author = "Giudice, {Maria Teresa} and Marco D’Indinosante and Serena Cappuccio and Valerio Gallotta and Anna Fagotti and Giovanni Scambia and Marco Petrillo",
year = "2018",
month = "11",
day = "1",
doi = "10.1007/s00404-018-4915-1",
language = "English",
volume = "298",
pages = "873--879",
journal = "Archives of Gynecology",
issn = "0170-9925",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Secondary cytoreduction in ovarian cancer

T2 - who really benefits?

AU - Giudice, Maria Teresa

AU - D’Indinosante, Marco

AU - Cappuccio, Serena

AU - Gallotta, Valerio

AU - Fagotti, Anna

AU - Scambia, Giovanni

AU - Petrillo, Marco

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Purpose: To identify women affected by recurrent ovarian cancer who benefit from secondary cytoreductive surgery (SCS), analyse their clinical and biological features and investigate the role of minimally invasive surgery (MIS) and hyperthermic intraperitoneal-based chemotherapy (HIPEC) in this subset of patients. Methods: This narrative review examines the data available from the updated literature. An electronic literature search was conducted in PubMed Medline databases for articles published from 1990 to 2018. Results: Retrospective studies and preliminary data from the AGO-Desktop III trial show that cytoreductive surgery is associated with improved post-relapse survival in patients with platinum-sensitive relapse, compared to chemotherapy alone. This benefit is more evident in patients treated with complete or optimal primary debulking surgery at referral centres, who did not receive bevacizumab in first-line chemotherapy, and who present a localized pattern of disease. MIS has been proven to be a favourable approach to achieve a complete secondary debulking, reducing peri- and postoperative comorbidities. The application of HIPEC to SCS is associated with an improvement in oncological outcomes by preliminary results. Conclusions: While waiting for the final results of the ongoing randomized controlled trials, SCS seems feasible and safe in selected patients with recurrent ovarian cancer. Recently, more attention has been focused on the biological features of ovarian tumours, such as BRCA status. Further studies and molecular research should be conducted to identify individualized and targeted therapies in the treatment of ovarian cancer recurrences.

AB - Purpose: To identify women affected by recurrent ovarian cancer who benefit from secondary cytoreductive surgery (SCS), analyse their clinical and biological features and investigate the role of minimally invasive surgery (MIS) and hyperthermic intraperitoneal-based chemotherapy (HIPEC) in this subset of patients. Methods: This narrative review examines the data available from the updated literature. An electronic literature search was conducted in PubMed Medline databases for articles published from 1990 to 2018. Results: Retrospective studies and preliminary data from the AGO-Desktop III trial show that cytoreductive surgery is associated with improved post-relapse survival in patients with platinum-sensitive relapse, compared to chemotherapy alone. This benefit is more evident in patients treated with complete or optimal primary debulking surgery at referral centres, who did not receive bevacizumab in first-line chemotherapy, and who present a localized pattern of disease. MIS has been proven to be a favourable approach to achieve a complete secondary debulking, reducing peri- and postoperative comorbidities. The application of HIPEC to SCS is associated with an improvement in oncological outcomes by preliminary results. Conclusions: While waiting for the final results of the ongoing randomized controlled trials, SCS seems feasible and safe in selected patients with recurrent ovarian cancer. Recently, more attention has been focused on the biological features of ovarian tumours, such as BRCA status. Further studies and molecular research should be conducted to identify individualized and targeted therapies in the treatment of ovarian cancer recurrences.

KW - Biological features

KW - Minimally invasive surgery

KW - Personalized treatment

KW - Recurrent ovarian cancer

KW - Secondary cytoreductive surgery

UR - http://www.scopus.com/inward/record.url?scp=85053859748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053859748&partnerID=8YFLogxK

U2 - 10.1007/s00404-018-4915-1

DO - 10.1007/s00404-018-4915-1

M3 - Review article

C2 - 30255344

AN - SCOPUS:85053859748

VL - 298

SP - 873

EP - 879

JO - Archives of Gynecology

JF - Archives of Gynecology

SN - 0170-9925

IS - 5

ER -